NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $73 | $58 | $34 | $23 |
| - Cash | $7 | $3 | $6 | $1 |
| + Debt | $0 | $10 | $8 | $7 |
| Enterprise Value | $67 | $66 | $36 | $28 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 59.9% | – | – | – |
| EBITDA | -$6 | -$18 | -$6 | -$9 |
| % Margin | -2,416.1% | – | – | – |
| Net Income | -$6 | -$18 | -$6 | -$9 |
| % Margin | -2,433.9% | – | – | – |
| EPS Diluted | -0.27 | -0.98 | -0.34 | -0.86 |
| % Growth | 72.4% | -188.2% | 60.5% | – |
| Operating Cash Flow | -$3 | -$4 | -$3 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$4 | -$3 | -$1 |